#405 Why Insurance Denies Genetic Testing, and How to Navigate Coverage
From DNA Today: A Genetics Podcast · · 34 min
This plays from the publisher's own server. We do not host a copy.
Description
Genetic testing can change the course of a patient’s care, but accessing the right test is not always straightforward.
Behind the scenes, insurance coverage decisions, documentation requirements, prior authorization, denials, appeals, and cost concerns can all influence whether a patient receives timely answers.
In this episode of DNA Today, we launch a new special series sponsored by Revvity (https://www.revvity.com/) in this episode exploring the health economics of genetic testing and the real-world systems that shape access to genomic medicine.
Host Kira Dineen is joined by Dr. Madhuri Hegde, Senior Vice President and Chief Scientific Officer at Revvity, and Mackenzie Mosera Derby, a pediatric genetic counselor at UW Health. Together, they examine genetic testing access from both the diagnostic laboratory and clinical perspectives exploring why insurance coverage remains so inconsistent, what goes into a prior authorization, why genetic tests are commonly denied, and how clinicians can approach appeals and peer-to-peer reviews.
In This Episode, We Discuss
- The transition from stacked laboratory procedure codes to codes for genes, panels, exomes, and genomes
- How and why insurance coverage varies among payers and individual health plans
- Coverage differences across hereditary cancer testing, exome sequencing, genome sequencing, reproductive testing, and population screening
- How rapid and ultra-rapid genome sequencing may be covered differently from standard genome sequencing
- The limited coverage available for preventive and population-based genomic testing
- The coordination required among patients, clinicians, laboratories, and insurance companies
- Why laboratories offering tests with similar names may differ in technology, interpretation, turnaround time, and clinical support
- What documentation is typically required for a genetic testing prior authorization
- How clinicians demonstrate medical necessity and clinical utility
- Why professional guidelines and peer-reviewed literature can strengthen an authorization request
- The role laboratories play in benefits investigations, billing assistance, financial support, and prior authorization
- Why laboratories may perform testing without knowing whether they will ultimately be reimbursed
- Common reasons insurance companies deny genetic testing
- Why “this test will not change clinical management” can be an overly narrow interpretation of genetic testing’s value
- How genetic results may inform surveillance, reproductive decisions, recurrence risks, family members, research eligibility, and patient support
- The role of hospital test utilization committees
- Why genetic counselors and geneticists should be represented on utilization review teams
- How letters of medical necessity (LOMN) and peer-to-peer reviews may support an appeal
- Why genetic counselors may be prevented from conducting peer-to-peer reviews, even when they were the ordering provider
- The time clinicians spend educating insurance representatives about genetics
- Why payer policies frequently lag behind genomic technology and professional recommendations
- The importance of detailed clinical documentation and accurate diagnostic coding
- The difference between prior authorization, insurance coverage, and guaranteed payment
- How self-pay pricing and misleading “no-cost” language can create confusion
- The potential devaluation of genetic testing and genetic counseling services through complementary or low cost self-pay options
- Why improving access requires collaboration among patients, clinicians, laboratories, professional organizations, healthcare systems, and payers
About The Guests Madhuri Hegde (https://www.revvity.com/meet-our-revvity-omics-global-experts), PhD, FACMG, is the Senior Vice President and Chief Scientific Officer at Revvity, where she leads the company’s scientific strategy and oversees Revvity Omics’ global network of laboratories.
Dr. Hegde…